Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $70.90M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 13.7× KraneShares Electric Vehicles and Future Mobility's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 48 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KARS | MRVI | |
|---|---|---|
Market Cap | $70.90M | $972.90M |
Volume | 2,312 | 4,325,710 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $9.00 |
52-Week Low | $26.72 | $2.83 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
